GPP
PLRX icon

Great Point Partners’s Pliant Therapeutics PLRX Stock Holding History

Great Point Partners’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-850,000
Closed -$1.26M – 40
2025
Q3 		$1.26M Hold
850,000
– – 0.52% 29
2025
Q2 		$986K Hold
850,000
– – 0.64% 25
2025
Q1 		$1.15M Sell
850,000
-205,000
-19% -$1.24M 0.61% 32
2024
Q4 		$13.9M Sell
1,055,000
-855,121
-45% -$11.7M 6.55% 5
2024
Q3 		$21.4M Sell
1,910,121
-726,743
-28% -$9.09M 6.3% 3
2024
Q2 		$28.3M Buy
2,636,864
+785,000
+42% +$10.1M 5.43% 5
2024
Q1 		$27.6M Buy
1,851,864
+28,680
+2% +$473K 4.3% 6
2023
Q4 		$33M Buy
1,823,184
+68,000
+4% +$1.03M 5.63% 4
2023
Q3 		$30.4M Buy
1,755,184
+205,000
+13% +$3.55M 5.54% 3
2023
Q2 		$28.1M Buy
1,550,184
+338,088
+28% +$8M 5.5% 4
2023
Q1 		$32.2M Sell
1,212,096
-110,774
-8% -$3.15M 6.33% 1
2022
Q4 		$25.6M Buy
1,322,870
+281,133
+27% +$5.88M 5.01% 5
2022
Q3 		$21.8M Buy
1,041,737
+684,474
+192% +$13.1M 5.24% 8
2022
Q2 		$2.86M Buy
+357,263
New +$2.29M 0.69% 32

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Great Point Partners's PLRX Position: Q4 2025 in Review

Great Point Partners sold out of Pliant Therapeutics (PLRX) in Q4 2025, closing a stake of 850,000 shares — an estimated $1.26M sold.

Great Point Partners first reported a position in PLRX in Q2 2022 and held it in 14 quarters. The position peaked at $33M in Q4 2023. 96 funds tracked by Wall St. Rank hold PLRX as of Q4 2025.

  • Great Point Partners reported no remaining Pliant Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Great Point Partners sold 850,000 Pliant Therapeutics shares in Q4 2025, an estimated $1.26M.
  • Great Point Partners first reported a position in Pliant Therapeutics in Q2 2022 and held it in 14 quarters.
  • Great Point Partners's Pliant Therapeutics position peaked at $33M in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2025.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.